Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology
Launched by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE · Dec 16, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Remote Resistance Exercise Powering Survivors," is looking at how a special exercise program delivered online can help people undergoing chemotherapy for advanced upper gastrointestinal (GI) cancer. The goal is to see if this remote exercise training can improve strength and overall well-being for those fighting this type of cancer.
To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of advanced upper GI cancer (stages III or IV). They should also be able to read and speak English and be planning to return to Moffitt Cancer Center for further treatment. While the trial is open to anyone meeting these criteria, it excludes those who already engage in regular resistance training, have certain health issues that could affect their ability to exercise safely, or experience significant pain. Participants can expect to take part in guided exercise sessions online, which will be tailored to their needs and abilities during their treatment journey.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Biopsy-proven upper GI cancer, stage III-IV
- • ECOG performance status 0-1
- • Treatment plan of chemotherapy with planned return to Moffitt Cancer Center for restaging
- • Able to read and speak English fluently
- • Capable of providing informed consent
- Exclusion Criteria:
- • Regular engagement in RT (2x/week targeting all major muscle groups)
- • Screen failure for exercise safety based on Physical Activity Readiness Questionnaire (PAR-Q) and Patient-Reported Measurement Information System (PROMIS) screening questions
- • Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV).
- • Recent fracture or acute musculoskeletal injury that precludes ability to participate in RT
- • Numeric pain rating scale of ≥ 7 out of 10
- • Myopathic or rheumatologic disease that impacts physical function
About H. Lee Moffitt Cancer Center And Research Institute
H. Lee Moffitt Cancer Center and Research Institute is a leading institution dedicated to cancer research, treatment, and education, recognized for its commitment to advancing cancer care through innovative clinical trials and groundbreaking research. As a National Cancer Institute-designated Comprehensive Cancer Center, Moffitt integrates cutting-edge science with patient-centered care, offering a multidisciplinary approach to cancer treatment. The center is at the forefront of developing novel therapies and improving outcomes for patients, emphasizing collaboration between researchers and clinicians to translate scientific discoveries into effective treatments. Through its extensive clinical trial programs, Moffitt aims to enhance the understanding of cancer biology and provide patients with access to the latest therapies and interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Patients applied
Trial Officials
Nathan Parker, PhD, MPH
Principal Investigator
Moffitt Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials